Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

Clinical trial NCT05044117 · RECRUITING

Trial details

NCT number: NCT05044117
Sponsor: Sun Yat-sen University
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma

Start date: 2021-10-18
Primary completion: 2026-10-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.